CR20190251A - Composiciones y métodos relacionados con agonistas de piridinoilpiperidina 5-ht 1f - Google Patents

Composiciones y métodos relacionados con agonistas de piridinoilpiperidina 5-ht 1f

Info

Publication number: CR20190251A
Authority: CR; Costa Rica
Prior art keywords: compositions; pyridinoylpiperidine; trifluoro; methods related; ht1f agonists
Prior art date: 2016-12-06

Application number

CR20190251A

Other languages

English (en)

Inventor

Emma Sharp

Paul Fagan

Raymond D Skwierczynski

Brigida Allieri

Original Assignee

Colucid Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-12-06

Filing date

2017-12-05

Publication date

2019-08-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60972336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20190251(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2017-12-05 Application filed by Colucid Pharmaceuticals Inc filed Critical Colucid Pharmaceuticals Inc

2019-08-26 Publication of CR20190251A publication Critical patent/CR20190251A/es

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CR20190251A 2016-12-06 2017-12-05 Composiciones y métodos relacionados con agonistas de piridinoilpiperidina 5-ht 1f CR20190251A (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201662430662P	2016-12-06	2016-12-06
PCT/US2017/064652 WO2018106657A1 (en)	2016-12-06	2017-12-05	Compositions and methods related to pyridinoylpiperidine 5-ht1f agonists

Publications (1)

Publication Number	Publication Date
CR20190251A true CR20190251A (es)	2019-08-26

Family

ID=60972336

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CR20190251A CR20190251A (es)	2016-12-06	2017-12-05	Composiciones y métodos relacionados con agonistas de piridinoilpiperidina 5-ht 1f

Country Status (38)

Country	Link
US (1)	US11053214B2 (es)
EP (1)	EP3551617B1 (es)
JP (4)	JP2020500936A (es)
KR (3)	KR20230008257A (es)
CN (3)	CN110291079A (es)
AU (1)	AU2017373784B2 (es)
BR (1)	BR112019010934A2 (es)
CA (1)	CA3043772C (es)
CL (1)	CL2019001426A1 (es)
CO (1)	CO2019005290A2 (es)
CR (1)	CR20190251A (es)
CY (1)	CY1124540T1 (es)
DK (1)	DK3551617T3 (es)
DO (1)	DOP2019000139A (es)
EA (1)	EA201991112A1 (es)
EC (1)	ECSP19040190A (es)
ES (1)	ES2889476T3 (es)
HR (1)	HRP20211557T1 (es)
HU (1)	HUE056820T2 (es)
IL (1)	IL266598B2 (es)
JO (1)	JOP20190129B1 (es)
LT (1)	LT3551617T (es)
MA (1)	MA52920B1 (es)
MD (1)	MD3551617T2 (es)
MX (2)	MX388091B (es)
MY (1)	MY196855A (es)
NZ (1)	NZ752906A (es)
PE (2)	PE20191134A1 (es)
PH (1)	PH12019501252B1 (es)
PL (1)	PL3551617T3 (es)
PT (1)	PT3551617T (es)
RS (1)	RS62415B1 (es)
SI (1)	SI3551617T1 (es)
TN (1)	TN2019000174A1 (es)
TW (1)	TWI671290B (es)
UA (1)	UA124433C2 (es)
WO (1)	WO2018106657A1 (es)
ZA (1)	ZA201903449B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5727457B2 (ja)	2009-04-02	2015-06-03	コルーシッドファーマシューティカルズ，インコーポレイテッド	２，４，６−トリフルオロ−ｎ−［６−（１−メチル−ピペリジン−４−カルボニル）−ピリジン−２−イル］−ベンズアミドの組成物
TWI826514B (zh)	2018-09-04	2023-12-21	美商美國禮來大藥廠	用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥
AR119319A1 (es)	2019-07-09	2021-12-09	Lilly Co Eli	Procesos e intermediario para la preparación a gran escala de hemisuccinato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il]-benzamida y preparación de acetato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il]-benzamida
CN111004214B (zh) *	2019-11-22	2021-06-08	广东东阳光药业有限公司	吡啶酰基哌啶衍生物及其用途
US12271057B1 (en)	2019-12-20	2025-04-08	The Uab Research Foundation	Chromatic aberration tuning ophthalmic corrector lens methods
JP2024517874A (ja)	2021-05-07	2024-04-23	イーライリリーアンドカンパニー	２，４，６－トリフルオロ－ｎ－［６－（１－メチル－ピペリジン－４－カルボニル）－ピリジン－２－イル］－ベンズアミドヘミコハク酸塩の味マスキングされた組成物、及びそれを含む経口崩壊錠剤
CN116270505A (zh) *	2021-12-20	2023-06-23	南京科默生物医药有限公司	含半琥珀酸拉司米地坦的口服固体制剂及其3d打印制备技术

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5023252A (en)	1985-12-04	1991-06-11	Conrex Pharmaceutical Corporation	Transdermal and trans-membrane delivery of drugs
US5011472A (en)	1988-09-06	1991-04-30	Brown University Research Foundation	Implantable delivery system for biological factors
TWI263497B (en) *	2002-03-29	2006-10-11	Lilly Co Eli	Pyridinoylpiperidines as 5-HT1F agonists
US20060178349A1 (en) *	2005-01-24	2006-08-10	Pozen Inc.	Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID
JP5727457B2 (ja)	2009-04-02	2015-06-03	コルーシッドファーマシューティカルズ，インコーポレイテッド	２，４，６−トリフルオロ−ｎ−［６−（１−メチル−ピペリジン−４−カルボニル）−ピリジン−２−イル］−ベンズアミドの組成物
WO2011123654A1 (en) *	2010-04-02	2011-10-06	Colucid Pharmaceuticals, Inc.	Compositions and methods of synthesis of pyridinoylpiperidine 5-ht1f agonists
WO2012163365A1 (en)	2011-06-01	2012-12-06	Concit Pharma Aps	Combinations of serotonin receptor agonists for treatment of movement disorders
WO2018010345A1 (zh)	2016-07-15	2018-01-18	杭州领业医药科技有限公司	一种受体激动剂的晶型及其制备方法和药物组合物
TWI754772B (zh)	2017-09-06	2022-02-11	美商美國禮來大藥廠	用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法

2017
- 2017-12-05 PT PT17829372T patent/PT3551617T/pt unknown
- 2017-12-05 PE PE2019001167A patent/PE20191134A1/es unknown
- 2017-12-05 JO JOP/2019/0129A patent/JOP20190129B1/ar active
- 2017-12-05 IL IL266598A patent/IL266598B2/en unknown
- 2017-12-05 PE PE2023002466A patent/PE20241297A1/es unknown
- 2017-12-05 HR HRP20211557TT patent/HRP20211557T1/hr unknown
- 2017-12-05 CN CN201780075750.7A patent/CN110291079A/zh active Pending
- 2017-12-05 US US16/467,208 patent/US11053214B2/en active Active
- 2017-12-05 MY MYPI2019003189A patent/MY196855A/en unknown
- 2017-12-05 EA EA201991112A patent/EA201991112A1/ru unknown
- 2017-12-05 JP JP2019551251A patent/JP2020500936A/ja active Pending
- 2017-12-05 DK DK17829372.6T patent/DK3551617T3/da active
- 2017-12-05 WO PCT/US2017/064652 patent/WO2018106657A1/en active Application Filing
- 2017-12-05 NZ NZ752906A patent/NZ752906A/en unknown
- 2017-12-05 TN TNP/2019/000174A patent/TN2019000174A1/en unknown
- 2017-12-05 LT LTEPPCT/US2017/064652T patent/LT3551617T/lt unknown
- 2017-12-05 MD MDE20191169T patent/MD3551617T2/ro unknown
- 2017-12-05 PH PH1/2019/501252A patent/PH12019501252B1/en unknown
- 2017-12-05 EP EP17829372.6A patent/EP3551617B1/en active Active
- 2017-12-05 KR KR1020227046438A patent/KR20230008257A/ko not_active Ceased
- 2017-12-05 RS RS20211233A patent/RS62415B1/sr unknown
- 2017-12-05 SI SI201730881T patent/SI3551617T1/sl unknown
- 2017-12-05 HU HUE17829372A patent/HUE056820T2/hu unknown
- 2017-12-05 MX MX2019006520A patent/MX388091B/es unknown
- 2017-12-05 CN CN202210944298.6A patent/CN115385893A/zh active Pending
- 2017-12-05 UA UAA201905483A patent/UA124433C2/uk unknown
- 2017-12-05 KR KR1020197016255A patent/KR20190075130A/ko not_active Ceased
- 2017-12-05 CN CN202210944373.9A patent/CN115385894A/zh active Pending
- 2017-12-05 KR KR1020217025499A patent/KR20210102497A/ko not_active Ceased
- 2017-12-05 ES ES17829372T patent/ES2889476T3/es active Active
- 2017-12-05 MA MA52920A patent/MA52920B1/fr unknown
- 2017-12-05 TW TW106142535A patent/TWI671290B/zh active
- 2017-12-05 CR CR20190251A patent/CR20190251A/es unknown
- 2017-12-05 BR BR112019010934A patent/BR112019010934A2/pt not_active Application Discontinuation
- 2017-12-05 PL PL17829372T patent/PL3551617T3/pl unknown
- 2017-12-05 MX MX2021014139A patent/MX392547B/es unknown
- 2017-12-05 AU AU2017373784A patent/AU2017373784B2/en active Active
- 2017-12-05 CA CA3043772A patent/CA3043772C/en active Active
2019
- 2019-05-23 CO CONC2019/0005290A patent/CO2019005290A2/es unknown
- 2019-05-27 CL CL2019001426A patent/CL2019001426A1/es unknown
- 2019-05-30 DO DO2019000139A patent/DOP2019000139A/es unknown
- 2019-05-30 ZA ZA2019/03449A patent/ZA201903449B/en unknown
- 2019-06-06 EC ECSENADI201940190A patent/ECSP19040190A/es unknown
2021
- 2021-09-22 JP JP2021153729A patent/JP2022000451A/ja active Pending
- 2021-10-05 CY CY20211100864T patent/CY1124540T1/el unknown
2023
- 2023-06-26 JP JP2023104019A patent/JP7561240B2/ja active Active
2024
- 2024-09-20 JP JP2024163884A patent/JP2024178323A/ja active Pending

Also Published As

Publication number	Publication date
BR112019010934A2 (pt)	2019-10-01
CL2019001426A1 (es)	2019-10-11
MX392547B (es)	2025-03-24
JOP20190129A1 (ar)	2019-05-29
MD3551617T2 (ro)	2021-12-31
AU2017373784B2 (en)	2020-04-23
KR20210102497A (ko)	2021-08-19
MA52920B1 (fr)	2021-11-30
ZA201903449B (en)	2021-02-24
TW201833097A (zh)	2018-09-16
CN115385893A (zh)	2022-11-25
US20200087279A1 (en)	2020-03-19
KR20190075130A (ko)	2019-06-28
PH12019501252A1 (en)	2019-12-02
ECSP19040190A (es)	2019-08-30
WO2018106657A1 (en)	2018-06-14
CN110291079A (zh)	2019-09-27
NZ752906A (en)	2021-07-30
EP3551617B1 (en)	2021-08-11
PH12019501252B1 (en)	2024-05-24
JP2020500936A (ja)	2020-01-16
CA3043772A1 (en)	2018-06-14
JP2022000451A (ja)	2022-01-04
IL266598B1 (en)	2024-01-01
EA201991112A1 (ru)	2019-10-31
PT3551617T (pt)	2021-10-04
PE20191134A1 (es)	2019-09-02
MX2021014139A (es)	2022-05-24
IL266598A (en)	2019-07-31
DK3551617T3 (da)	2021-09-13
MX2019006520A (es)	2019-08-21
CO2019005290A2 (es)	2019-05-31
UA124433C2 (uk)	2021-09-15
HUE056820T2 (hu)	2022-03-28
CN115385894A (zh)	2022-11-25
PE20241297A1 (es)	2024-06-24
JP7561240B2 (ja)	2024-10-03
CA3043772C (en)	2022-06-07
JP2023123678A (ja)	2023-09-05
JP2024178323A (ja)	2024-12-24
KR20230008257A (ko)	2023-01-13
AU2017373784A1 (en)	2019-05-16
IL266598B2 (en)	2024-05-01
LT3551617T (lt)	2021-10-11
DOP2019000139A (es)	2019-08-15
EP3551617A1 (en)	2019-10-16
MA52920A (fr)	2021-04-28
SI3551617T1 (sl)	2021-11-30
JOP20190129B1 (ar)	2023-03-28
RS62415B1 (sr)	2021-10-29
MX388091B (es)	2025-03-19
TN2019000174A1 (en)	2020-10-05
PL3551617T3 (pl)	2021-12-20
HRP20211557T1 (hr)	2022-01-07
ES2889476T3 (es)	2022-01-12
MY196855A (en)	2023-05-05
CY1124540T1 (el)	2022-07-22
TWI671290B (zh)	2019-09-11
US11053214B2 (en)	2021-07-06

Publication	Publication Date	Title
CR20190251A (es)	2019-08-26	Composiciones y métodos relacionados con agonistas de piridinoilpiperidina 5-ht 1f
CL2019001344A1 (es)	2020-02-21	Composición farmacéutica para prevenir o tratar el cáncer de cerebro incluyendo el polimorfo cristalino del hexoxido tetraarsenico y el método para preparar el mismo.
MX2022001299A (es)	2022-05-10	Composiciones y métodos para unir dominios extracelulares de tipo i y tipo ii como proteínas quiméricas heterólogas.
ZA201901924B (en)	2024-05-30	Anti¿lag¿3 antibodies and compositions
PH12019500204A1 (en)	2020-01-20	Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2019003623A (es)	2019-09-23	Composiciones y metodos para el tratamiento de afecciones oftalmicas.
MX2018009773A (es)	2018-11-29	Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4).
EA201692201A1 (ru)	2017-08-31	Соединения и композиции в качестве агонистов toll-подобного рецептора 7
MX2016012779A (es)	2017-04-27	Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40.
MX2018006632A (es)	2018-11-09	Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4).
MX2018009325A (es)	2019-05-15	Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
MX2018006700A (es)	2019-02-20	Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
MX388562B (es)	2025-03-20	Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal.
MY180844A (en)	2020-12-10	Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MX2016008953A (es)	2017-02-02	Composiciones farmaceuticas que comprenden i5-hidroxi-eicosa- 5,8,11,13,17-pentaenoico ( 15-hepe ) y metodos para tratar el asma y trastornos pulmonares que usan las mismas.
MX2019005089A (es)	2019-09-10	Anticuerpos anti cumulo de diferenciacion 40 (cd40) en combinacion y metodos de uso.
PH12016501393B1 (en)	2017-02-06	Substituted bicyclic heteroaryl compounds as rxr agonists
MX382453B (es)	2025-03-13	Composiciones y metodos para tratar enfermedades neurodegenerativas
MX2015009153A (es)	2016-03-04	Uso de agonistas del receptor nicotinico de acetilcolina alfa 7.
MX2017007318A (es)	2017-08-25	Metodos de prevencion, reduccion o tratamiento de degeneracion macular.
MA40642A (fr)	2016-03-31	Nouveaux dérivés peptidiques et leurs utilisations
EA201791450A1 (ru)	2017-12-29	3,5-диаминопиразоловые ингибиторы киназы
MX2019005294A (es)	2019-10-14	Inhibidores de las interacciones de mtor-deptor y metodos de uso de los mismos.
MX2018004091A (es)	2018-07-06	Antagonistas de il-17c para el tratamiento y/o prevencion de dermatitis atopica.
MX2018010174A (es)	2019-01-10	INHIBIDORES DE INTERACCIONES DE RECEPTOR DE ß-ARRESTINA-NEUROCININ A 1 PARA EL TRATAMIENTO DEL DOLOR.